CN1321684A - Novel polypeptide-human KRAB occluded zinc finger protein KRA 22-12 and polynucleotide for coding this polypeptide - Google Patents

Abstract

The present invention discloses a novel polypeptide-human KRA3 included zinc finger protein KRAZ2-12, polynucleotide for coding said polypeptide and method for producing this polypeptide by using DNA recombination technology. Said invention also discloses the method for curing several diseases, such as various tumors, diseases of nervous system, development disturbance, hemopathy, some hereditary diseases, diseases of endocrine system and diseases of immunological system by using said polypeptide. Said invention also discloses an antagonist for resisting said polypeptide and its therapeutic action, and also discloses the application of polynucleotide for coding this novel human KRA3 included zinc finger protein KRAZ2-12.

Description

A kind of new polypeptide--the zinc finger protein KRAZ2-12 that people KRAB comprises and the polynucleotide of this peptide species of coding

The invention belongs to biological technical field, specifically, the invention describes a kind of new polypeptide--the zinc finger protein KRAZ2-12 that people KRAB comprises, and the polynucleotide sequence of this polypeptide of encoding.The invention still further relates to the preparation method and the application of these polynucleotide and polypeptide.

To studies show that in a large number of the transcriptional activity factor, the functional area of many transcription factors is medellings, can be divided into DNA calmodulin binding domain CaM and effect (activate or check) zone on structure function.Wherein have a kind of for the similar C2H2 type of Kruppel zinc finger protein (Kruppel-like ZFPs), comprise very conservative Kruppel box (Kruppel-related box, KRAB).

The KRAB box is considered to structural domain conservative in a kind of evolve at first, has comprised 75 amino acid, and is present in about 1/3rd the Kruppel type zinc finger protein (Bellefroid, E.J., Poncelet, D.A.etal., 1991).KRAB can also be divided into KRAB-A and two kinds of zones of KRAB-B.All have the KRAB-A zone in any one KRAB, but KRAB-B is really not so, it is for some containment of transcribing work (Margolin, R., Friedman, J.R.et al, 1994; Witzgall, R., O ' Leary, E.et al., 1994).KRAB is rich in the zone and has electrical amino acid, may be folded into and be with amphiphilic alpha-helix, as the protein-protein interaction zone, with other Ala or Pro be rich in the zone different, the KRAB zone is a high conservative in Kruppel type zinc finger protein subfamily.

KRAZl and KRAZ2 are the zinc finger proteins that comprises the KRAB box, and the cBNA of KRAZ1 comprises an open reading frame, encode one to contain 652 amino acid whose albumen; One of the cDNA coding of KRAZ2 contains 606 amino acid whose albumen, and its molecular weight is about 71.2Kd.The N-terminal of KRAZ1 and KRAZ2 all comprises the KRAB-A zone, and C-terminal all contains multiple Zinc finger domain (being respectively 15 and 9 copy numbers).Yet the KRAB-A zone of KRAZ2 is followed by KRAB-B (Bellefroid, E.J., Poncelet, D.A.et al., 1991), and KRAZ1 is really not so.KRAZ1 and KRAZ2 have expression in the nearly all tissue of Mammals.

KRAZ1 and KRAZ2 have the adjusting transcriptional activity.The repressor activity is by corepressor KAP-1 mediation, and KRAZ1/2 can be attached to KAP-1, and product can not react with KAP-1 but the KRAB of KRAZ1/2 suddenlys change, and causes checking active lacking.KAP-1 has the activity that checks in essence, has promoted checking of KRAB1/2 mediation.Activation is checked mechanism and is related to specific proteins-protein-interacting, does not directly rely on the interaction that component sees and finishes the process that activation is checked yet also have.Transcribe in vivo in the experiment, except activation was transcribed, KPAB can also check basic promotion factor active.

Polypeptide of the present invention and above-mentioned KRAZ2 have 71% homogeny, 84% similarity, and comprise its distinctive conserved sequence, therefore think that this albumen is a kind of new adjusting transcriptional activity albumen, have the biological function similar, and name the zinc finger protein KRAZ2-12 that comprises for people KRAB to KRAZ2.

Because the zinc finger protein KRAZ2-12 albumen that comprises of people KRAB plays an important role in regulating body critical functions such as cell fission and fetal development as mentioned above, and believe and relate to a large amount of albumen in these regulate processes, thereby the zinc finger protein KRAZ2-12 albumen that comprises of the people KRAB that always needs to identify more these processes of participation in this area, particularly identify this proteic aminoacid sequence.The separation of the zinc finger protein KRAZ2-12 protein coding gene that new person KRAB comprises also provides the foundation for determining the effect of this albumen under healthy and morbid state.This albumen may constitute the basis of exploitation medical diagnosis on disease and/or curative, and it is very important therefore separating its coding DNA.

An object of the present invention is to provide isolating new polypeptide--zinc finger protein KRAZ2-12 that people KRAB comprises with and fragment, analogue and derivative.

Another object of the present invention provides the polynucleotide of this polypeptide of coding.

Another object of the present invention provides the recombinant vectors of the polynucleotide that contain the zinc finger protein KRAZ2-12 that coding people KRAB comprises.

Another object of the present invention provides the genetically engineered host cell of the polynucleotide that contain the zinc finger protein KRAZ2-12 that coding people KRAB comprises.

Another object of the present invention provides the method for producing the zinc finger protein KRAZ2-12 that people KRAB comprises.

Another object of the present invention provides at polypeptide of the present invention--the antibody of the zinc finger protein KRAZ2-12 that people KRAB comprises.

Another object of the present invention has provided at polypeptide of the present invention--simulated compound, antagonist, agonist, the inhibitor of the zinc finger protein KRAZ2-12 that people KRAB comprises.

Another object of the present invention provides the method for the unusual relevant disease of zinc finger protein KRAZ2-12 that diagnoses and treatment and people KRAB comprise.

The present invention relates to a kind of isolated polypeptide, this polypeptide is the people source, and it comprises: polypeptide or its examples of conservative variations, bioactive fragment or derivative with SEQ ID No.2 aminoacid sequence.Preferably, this polypeptide is the polypeptide with SEQ ID NO:2 aminoacid sequence.

The invention still further relates to a kind of isolating polynucleotide, it comprises a kind of nucleotide sequence or its variant that is selected from down group:

(a) coding has the polynucleotide of the polypeptide of SEQ ID No.2 aminoacid sequence;

(b) with polynucleotide (a) complementary polynucleotide;

(c) with (a) or polynucleotide sequence (b) have the polynucleotide of at least 72% homogeny.

More preferably, the sequence of these polynucleotide is be selected from down group a kind of: the sequence that (a) has 39-362 position among the SEQ ID NO:1; (b) has the sequence of 1-1050 position among the SEQ ID NO:1.

The present invention relates to a kind of carrier that contains polynucleotide of the present invention, particularly expression vector in addition; The host cell that this carrier of a kind of usefulness is genetically engineered comprises the host cell of conversion, transduction or transfection; A kind of method for preparing polypeptide of the present invention of cultivating described host cell and reclaiming expression product that comprises.

The invention still further relates to a kind of can with polypeptid specificity bonded antibody of the present invention.

The invention still further relates to a kind of simulation, activation, antagonism of screening or suppress the method for the compound of the zinc finger protein KRAZ2-12 protein-active that people KRAB comprises, it comprises and utilizes polypeptide of the present invention.The invention still further relates to the compound that obtains with this method.

The invention still further relates to a kind of vitro detection and express the relevant disease or the method for disease susceptibility with the zinc finger protein KRAZ2-12 abnormal protein that people KRAB comprises, comprise the sudden change in polypeptide described in the detection of biological sample or its coded polynucleotide sequence, perhaps the amount or the biological activity of polypeptide of the present invention in the detection of biological sample.

The present invention also relates to a kind of pharmaceutical composition, it contains polypeptide of the present invention or its stand-in, activator, antagonist or inhibitor and pharmaceutically acceptable carrier.

The invention still further relates to polypeptide of the present invention and/or polynucleotide and be used for the treatment of cancer, developmental character disease or immunological disease or other because the purposes of the medicine of the zinc finger protein KRAZ2-12 disease that abnormal expression causes that people KRAB comprises in preparation.

Others of the present invention are because disclosing of the technology of this paper is conspicuous to those skilled in the art.

The following term of using in this specification sheets and claims has following implication unless stated otherwise:

" nucleotide sequence " is meant oligonucleotide, Nucleotide or polynucleotide and fragment or part, also can refer to genome or synthetic DNA or RNA, and they can be strand or two strands, represent sense strand or antisense strand.Similarly, term " aminoacid sequence " is meant oligopeptides, peptide, polypeptide or protein sequence and fragment or part.When " aminoacid sequence " among the present invention related to a kind of aminoacid sequence of naturally occurring protein molecule, this " polypeptide " or " protein " did not mean that aminoacid sequence are restricted to the complete natural amino acid relevant with described protein molecule.

Protein or polynucleotide " variant " are meant a kind of polynucleotide sequence that has the aminoacid sequence of one or more amino acid or Nucleotide change or encode it.Described change can comprise disappearance, insertion or the replacement of amino acid in aminoacid sequence or the nucleotide sequence or Nucleotide.Variant can have " conservative property " and change, and wherein the amino acid of Ti Huaning has structure or the chemical property similar with original acid, as replacing Isoleucine with leucine.Variant also can have non-conservation and change, as replacing glycine with tryptophane.

" disappearance " is meant the disappearance of in aminoacid sequence or nucleotide sequence one or more amino acid or Nucleotide.

" insertion " or " interpolation " is meant that the change in aminoacid sequence or nucleotide sequence causes comparing the increase of one or more amino acid or Nucleotide with naturally occurring molecule." replacement " is meant by different amino acid or Nucleotide and replaces one or more amino acid or Nucleotide.

" biological activity " is meant the protein of structure, regulation and control or biochemical function with natural molecule.Similarly, term " immunologic competence " be meant natural, reorganization or synthetic protein and fragment thereof in suitable animal or cell, induce specific immune response and with specific antibody bonded ability.

" agonist " is meant when when zinc finger protein KRAZ2-12 that people KRAB comprises combines, thereby a kind of this protein that causes changes the molecule of regulating this protein active.Agonist can comprise the molecule of protein, nucleic acid, carbohydrate or any zinc finger protein KRAZ2-12 that other can comprise in conjunction with people KRAB.

" antagonist " or " inhibition " is meant when when zinc finger protein KRAZ2-12 that people KRAB comprises combines, a kind of sealing or the biologic activity of the zinc finger protein KRAZ2-12 that mediator KRAB comprises or the molecule of immunologic competence.Antagonist and inhibition can comprise the molecule of protein, nucleic acid, carbohydrate or any zinc finger protein KRAZ2-12 that other can comprise in conjunction with people KRAB.

" adjusting " is meant that the function of the zinc finger protein KRAZ2-12 that people KRAB comprises changes, and comprises the change of any other biological property, function or the immune property of the rising of protein active or reduction, the change of binding characteristic and the zinc finger protein KRAZ2-12 that people KRAB comprises.

The pure basically ＂ of ＂ is meant and is substantially free of natural relative other albumen, lipid, carbohydrate or other material.The zinc finger protein KRAZ2-12 that those skilled in the art can comprise with the purified technology of protein purifying people KRAB of standard.Basically the zinc finger protein KRAZ2-12 that pure people KRAB comprises can produce single master tape on the irreducibility polyacrylamide gel.The purity available amino end acid sequence analysis of the zinc finger protein KRAZ2-12 polypeptide that people KRAB comprises.

" complementary " or " complementation " is meant under salt concn that allows and temperature condition by the natural combination of the polynucleotide of base pairing.For example, sequence " C-T-G-A " can combine with complementary sequence " G-A-C-T ".Complementation between two single chain molecules can be part or whole.Complementary degree between the nucleic acid chains has a significant effect for efficient of hybridizing between the nucleic acid chains and intensity.

" homology " is meant the complementary degree, can be portion homologous or complete homology." portion homologous " is meant a kind of part complementary sequence, and it can partly suppress the hybridization of complete complementary sequence and target nucleic acid at least.The inhibition of this hybridization can detect by hybridizing (Southern trace or Northern trace etc.) under the condition that reduces in the severity degree.Basically homologous sequence or hybridization probe can compete and suppress complete homologous sequence and target sequence the condition that reduces of severity degree under combine.This does not mean the conditions permit non-specific binding that the severity degree reduces because the conditional request two sequences that the severity degree reduces mutual be combined into specificity or selectivity interacts.

" homogeny percentage " be meant two or more amino acid or nucleotide sequence relatively in the same or analogous percentage of sequence.The available electron method is measured the homogeny percentage, as passing through MEGALIGN program (Lasergenesoftware package, DNASTAR, Inc., Madison Wis.).The MEGALIGN program can compare two or more sequences (Higgins, D.G. and P.M.Sharp (1988) Gene 73:237-244) according to diverse ways such as Cluster method.The cluster method is organized the series arrangement cluster by checking the distance between all pairings with each.Then with each bunch with in pairs or become set of dispense.Homogeny percentage between two aminoacid sequences such as sequence A and the sequence B calculates by following formula:

The residue number of mating between sequence A and the sequence B

100

Interval residue number in the residue number-sequence B of interval in the residue number-sequence A of sequence A

Also can be by the Cluster method or with the homogeny percentage (Hein J., (1990) Methods in emzumology 183:625-645) between known method in this area such as the Jotun Hein mensuration nucleotide sequence.

" similarity " is meant the degree that the identical or conservative property of corresponding position amino-acid residue when arranging contrast between the aminoacid sequence replaces.For example be used for amino acid that conservative property replaces, electronegative amino acid can comprise aspartic acid and L-glutamic acid; Positively charged amino acid can comprise Methionin and arginine; Having uncharged head group has similar hydrophilic amino acid can comprise leucine, Isoleucine and Xie Ansuan; Glycine and L-Ala; L-asparagine and glutamine; Serine and Threonine; Phenylalanine and tyrosine.

" antisense " is meant and specific DNA or RNA sequence complementary nucleotide sequence." antisense strand " is meant and " sense strand " complementary nucleic acid chains.

" derivative " is meant HFP or encodes its chemical modification object of nucleic acid.This chemical modification object can be with alkyl, acyl group or the amino hydrogen atom of replacing.The nucleic acid derivative codified keeps the polypeptide of the main biological characteristics of natural molecule.

" antibody " is meant complete antibody molecule and fragment thereof, as Fa, F (ab ') ₂And Fv, the antigenic determinant of the zinc finger protein KRAZ2-12 that it can specificity comprises in conjunction with people KRAB.

" humanized antibody " is meant that the aminoacid sequence in non-antigen binding domain territory is replaced and becomes more similar to people's antibody, but still keep original in active antibody.

" isolating " speech refers to material is shifted out among its original environment (for example, if spontaneous its natural surroundings that just refers to).Such as it is exactly not to be separated that spontaneous polynucleotide or polypeptide are present in the Live Animals, but same polynucleotide or polypeptide with some or all in natural system with it the material of coexistence separately be exactly isolating.Such polynucleotide may be the parts of a certain carrier, the part that also possible such polynucleotide or polypeptide are a certain composition.Since carrier or composition are not the compositions of its natural surroundings, they remain isolating.

As used herein, " isolating " are meant that material separates (if natural substance, primal environment promptly is a natural surroundings) from its primal environment.Do not have separation and purification as polynucleotide under the native state in the active somatic cell and polypeptide, but same polynucleotide or polypeptide as from native state with in other materials that exist separately, then for separation and purification.

As used herein, " the zinc finger protein KRAZ2-12 that isolating people KRAB comprises " is meant that the zinc finger protein KRAZ2-12 that people KRAB comprises is substantially free of natural relative other albumen, lipid, carbohydrate or other material.The zinc finger protein KRAZ2-12 that those skilled in the art can comprise with the purified technology of protein purifying people KRAB of standard.Basically pure polypeptide can produce single master tape on non-reduced polyacrylamide gel.The purity of the zinc finger protein KRAZ2-12 polypeptide that people KRAB comprises can be used amino acid sequence analysis.

The invention provides a kind of new polypeptide--the zinc finger protein KRAZ2-12 that people KRAB comprises, it is made up of the aminoacid sequence shown in the SEQ ID NO:2 basically.Polypeptide of the present invention can be recombinant polypeptide, natural polypeptides, synthetic polypeptide, preferred recombinant polypeptide.Polypeptide of the present invention can be the product of natural purifying, or the product of chemosynthesis, or uses recombinant technology to produce from protokaryon or eucaryon host (for example, bacterium, yeast, higher plant, insect and mammalian cell).The host used according to the recombinant production scheme, polypeptide of the present invention can be glycosylated, maybe can be nonglycosylated.Polypeptide of the present invention also can comprise or not comprise initial methionine residues.

The present invention also comprises fragment, derivative and the analogue of the zinc finger protein KRAZ2-12 that people KRAB comprises.As used herein, term " fragment ", " derivative " are meant identical biological function or the active polypeptide of zinc finger protein KRAZ2-12 that keeps people KRAB of the present invention to comprise basically with " analogue ".The fragment of polypeptide of the present invention, derivative or analogue can be: (I) is a kind of like this, wherein one or more amino-acid residues are replaced by conservative or non-conservative amino acid residues (preferably conservative amino acid residues), and the amino acid that replaces can be also can not encoded by genetic codon; Perhaps (II) is a kind of like this, and certain group on wherein one or more amino-acid residues is replaced by other group and comprises substituting group; Perhaps (III) is a kind of like this, and wherein mature polypeptide and another kind of compound (such as the compound that prolongs the polypeptide transformation period, for example polyoxyethylene glycol) merge; Perhaps (IV) is a kind of like this, wherein additional aminoacid sequence is integrated into mature polypeptide and the peptide sequence that forms (as leader sequence or secretion sequence or be used for the sequence or the proteinogen sequence of this polypeptide of purifying) by the elaboration of this paper, such fragment, derivative and analogue are considered within those skilled in the art's ken.

The invention provides isolating nucleic acid (polynucleotide), substantially the polynucleotide that have a polypeptide of SEQ ID NO:2 aminoacid sequence by coding are formed.Polynucleotide sequence of the present invention comprises the nucleotide sequence of SEQ ID NO:1.Polynucleotide of the present invention are to find from the cDNA library of people's fetal brain tissue.The polynucleotide sequence total length that it comprises is 1050 bases, its open reading frame 39-362 107 amino acid of having encoded.Find relatively that according to amino acid sequence homologous this polypeptide and KRAZ2 have 75% homology, deducibility goes out the zinc finger protein KRAZ2-12 that this people KRAB comprises and has the similar 26S Proteasome Structure and Function of KRAZ2.

Polynucleotide of the present invention can be dna form or rna form.Dna form comprises the DNA of cDNA, genomic dna or synthetic.DNA can be strand or double-stranded.DNA can be coding strand or noncoding strand.The coding region sequence of encoding mature polypeptide can be identical with the coding region sequence shown in the SEQ ID NO:1 or the varient of degeneracy.As used herein, " varient of degeneracy " are meant that in the present invention coding has protein or the polypeptide of SEQ ID NO:2, but with the differentiated nucleotide sequence of coding region sequence shown in the SEQ ID NO:1.

The polynucleotide of the mature polypeptide of coding SEQ ID NO:2 comprise: the encoding sequence that has only mature polypeptide; The encoding sequence of mature polypeptide and various additional code sequence; Encoding sequence of mature polypeptide (with optional additional code sequence) and non-coding sequence.

Term " polynucleotide of coded polypeptide " is meant polynucleotide that comprise this polypeptide of encoding and the polynucleotide that comprise additional code and/or non-coding sequence.

The invention still further relates to the varient of foregoing description polynucleotide, its coding has the polypeptide of identical aminoacid sequence or segment, analogue and the derivative of polypeptide with the present invention.The varient of these polynucleotide can be the allelic variant of natural generation or the varient that non-natural takes place.These nucleotide diversity bodies comprise and replace varient, deletion mutation body and insert varient.As known in the art, allelic variant is the replacement form of polynucleotide, and it may be replacement, disappearance or the insertion of one or more Nucleotide, but can be from not changing the function of its encoded polypeptides in fact.

The invention still further relates to and the polynucleotide (have at least 50% between two sequences, preferably have 70% homogeny) of sequence hybridization described above.The present invention be more particularly directed under stringent condition and the interfertile polynucleotide of polynucleotide of the present invention.In the present invention, " stringent condition " is meant: (1) than hybridization under low ionic strength and the comparatively high temps and wash-out, as 0.2 * SSC, and 0.1%SDS, 60 ℃; Or (2) hybridization the time adds and to use denaturing agent, as 50% (v/v) methane amide, 0.1% calf serum/0.1%Ficoll, 42 ℃ etc.; Or (3) only at the homogeny between the two sequences at least more than 95%, be more preferably 97% and just hybridize when above.And the polypeptide of interfertile polynucleotide encoding has identical biological function and activity with the mature polypeptide shown in the SEQ ID NO:2.

The invention still further relates to nucleic acid fragment with sequence hybridization described above.As used herein, " nucleic acid fragment " length contain 10 Nucleotide at least, better be 20-30 Nucleotide at least, be more preferably 50-60 Nucleotide at least, preferably more than at least 100 Nucleotide.Nucleic acid fragment also can be used for the amplification technique (as PCR) of nucleic acid to determine and/or to separate the polynucleotide of the zinc finger protein KRAZ2-12 that coding people KRAB comprises.

Polypeptide among the present invention and polynucleotide preferably provide with isolating form, more preferably are purified to homogeneous.

The special polynucleotide sequence of the zinc finger protein KRAZ2-12 that coding people KRAB of the present invention comprises can obtain with several different methods.For example, separate polynucleotide with hybridization technique well known in the art.These technology including, but not limited to: 1) with probe and genome or the hybridization of cDNA library to detect homologous polynucleotide sequence and 2) antibody screening of expression library to be to detect the polynucleotide passage of the clone with common structure feature.

Sequence dna fragment of the present invention also can obtain with following method: 1) separate double chain DNA sequence from genomic dna; 2) the chemical synthesising DNA sequence is to obtain the double-stranded DNA of described polypeptide.

In the above-mentioned method of mentioning, isolation of genomic DNA is least commonly used.The direct chemical of dna sequence dna is synthetic to be the method for often selecting for use.The more frequent method of selecting for use is the separation of cDNA sequence.The standard method that separates interested cDNA is from the donorcells separating mRNA of this gene of high expression level and carries out reverse transcription, forms plasmid or phage cDNA library.Extract the existing multiple proven technique of method of mRNA, test kit also can obtain (Qiagene) from commercial channels.And the construction cDNA library also is usual method (Sambrook, et al., MolecularCloning, A Laboratory Manual, Cold Spring Harbor Laboratory.New York, 1989).Also can obtain the cDNA library of commercial offers, as the different cDNA library of Clontech company.When being used in combination the polymeric enzyme reaction technology, even few expression product also can be cloned.

Available ordinary method is screened gene of the present invention from these cDNA libraries.These methods include, but is not limited to: (1) DNA-DNA or DNA-RNA hybridization; (2) appearance of marker gene function or forfeiture; (3) measure the level of the transcript of the zinc finger protein KRAZ2-12 that people KRAB comprises; (4), detect the protein product of genetic expression by immunological technique or mensuration biologic activity.Aforesaid method can singly be used, but also several different methods combined utilization.

In (1) kind method, hybridizing used probe is and any a part of homology of polynucleotide of the present invention that at least 10 Nucleotide of its length better are at least 30 Nucleotide, are more preferably at least 50 Nucleotide, preferably at least 100 Nucleotide.In addition, within 2000 Nucleotide, preferable is within 1000 Nucleotide to the length of probe usually.Probe used herein is the dna sequence dna of chemosynthesis on the basis of gene order information of the present invention normally.Gene of the present invention itself or fragment are certainly as probe.The mark of dna probe can be used radio isotope, fluorescein or enzyme (as alkaline phosphatase) etc.

In (4) kind method, the protein product of the zinc finger protein KRAZ2-12 genetic expression that detection people KRAB comprises can be used immunological technique such as Western blotting, radioimmunoprecipitation, enzyme-linked immunosorbent assay (ELISA) etc.

Use method (Saiki, the et al.Science1985 of round pcr DNA amplification/RNA; 230:1350-1354) be optimized for acquisition gene of the present invention.When particularly being difficult to from the library, obtain the cDNA of total length, can preferably use RACE method (the terminal rapid amplifying method of RACE-cDNA), the primer that is used for PCR can suitably be selected according to polynucleotide sequence information of the present invention disclosed herein, and available ordinary method is synthetic.Available ordinary method is as the DNA/RNA fragment by gel electrophoresis separation and purifying amplification.

The gene of the present invention that obtains as mentioned above, perhaps the polynucleotide sequence of various dna fragmentations etc. can with ordinary method such as dideoxy chain termination (Sanger et al.PNAS, 1977,74:5463-5467) measure.This class polynucleotide sequence is measured also available commercial sequencing kit etc.In order to obtain the cDNA sequence of total length, order-checking need be carried out repeatedly.Sometimes need to measure a plurality of clones' cDNA sequence, just can be spliced into the cDNA sequence of total length.

The present invention also relates to comprise the carrier of polynucleotide of the present invention, and the host cell that produces through genetically engineered of the zinc finger protein KRAZ2-12 encoding sequence that comprises with the carrier of the present invention or the KRAB that directly chooses, and the method that produces polypeptide of the present invention through recombinant technology.

Among the present invention, the polynucleotide sequence of the zinc finger protein KRAZ2-12 that coding people KRAB comprises can be inserted in the carrier, contains the recombinant vectors of polynucleotide of the present invention with formation.Term " carrier " refers to that bacterial plasmid well known in the art, phage, yeast plasmid, vegetable cell virus, mammalian cell virus are as adenovirus, retrovirus or other carrier.The carrier of Shi Yonging includes but not limited in the present invention: and the expression vector based on the T7 promotor of in bacterium, expressing (Rosenberg, et al.Gene, 1987,56:125); The pMSXND expression vector of in mammalian cell, expressing (Lee and Nathans, J Bio Chem.263:3521,1988) and at the carrier that derives from baculovirus of expressed in insect cells.In a word, as long as can duplicate in host and stablize, any plasmid and carrier may be used to make up recombinant expression vector.A key character of expression vector is to contain replication origin, promotor, marker gene and translational control element usually.

Method well-known to those having ordinary skill in the art can be used to make up the dna sequence dna that contains the zinc finger protein KRAZ2-12 that coding people KRAB comprises and the expression vector of suitable transcribing/translational control element.These methods comprise (Sambroook, et al.MolecularCloning, a Laboratory Manual, cold Spring Harbor Laboratory.New York, 1989) such as extracorporeal recombinant DNA technology, DNA synthetic technology, the interior recombinant technologys of body.Described dna sequence dna can effectively be connected on the suitable promotor in the expression vector, and is synthetic to instruct mRNA.The representative example of these promotors has: colibacillary lac or trp promotor; The P of lambda particles phage _LPromotor; Eukaryotic promoter comprises LTRs and some other known may command gene expression promoter in prokaryotic cell prokaryocyte or eukaryotic cell or its virus of CMV immediate early promoter, HSV thymidine kinase promoter, early stage and late period SV40 promotor, retrovirus.Expression vector also comprises ribosome bind site that translation initiation is used and transcription terminator etc.Inserting enhancer sequence in carrier will make its transcribing in higher eucaryotic cells be enhanced.Enhanser is the cis acting factor that DNA expresses, and nearly 10 to 300 base pairs act on promotor transcribing with enhancing gene usually.Can for example be included in the SV40 enhanser of 100 to 270 base pairs of replication origin side in late period one, at the polyoma enhanser of replication origin side in late period one and adenovirus enhanser etc.

In addition, expression vector preferably comprises one or more selected markers, to be provided for selecting the phenotypic character of transformed host cells, cultivate Tetrahydrofolate dehydrogenase, neomycin resistance and the green fluorescent protein (GFP) of usefulness as eukaryotic cell, or be used for colibacillary tsiklomitsin or amicillin resistance etc.

Persons skilled in the art all know how to select appropriate carriers/transcriptional regulatory element (as promotor, enhanser etc.) and selected marker.

Among the present invention, the polynucleotide of the zinc finger protein KRAZ2-12 that coding people KRAB comprises or the recombinant vectors that contains these polynucleotide can transform or transduce into host cell, contain the genetically engineered host cell of these polynucleotide or recombinant vectors with formation.Term " host cell " refers to prokaryotic cell prokaryocyte, as bacterial cell; Or eukaryotic cell such as low, as yeast cell; Or higher eucaryotic cells, as mammalian cell.Representative example has: intestinal bacteria, streptomyces; Bacterial cell such as Salmonella typhimurium; Fungal cell such as yeast; Vegetable cell; Insect cell such as fruit bat S2 or Sf9; Zooblast such as CHO, COS or Bowes melanoma cells etc.

Can carry out with routine techniques well known to those skilled in the art with dna sequence dna of the present invention or the recombinant vectors transformed host cell that contains described dna sequence dna.When the host was prokaryotic organism such as intestinal bacteria, the competent cell that can absorb DNA can be used CaCl in exponential growth after date results ₂Method is handled, and used step is well-known in this area.Alternative is to use MgCl ₂If desired, transforming also the method for available electroporation carries out.When the host is an eukaryote, can select following DNA transfection method for use: coprecipitation of calcium phosphate method, perhaps conventional mechanical method such as microinjection, electroporation, liposome packing etc.

By the recombinant DNA technology of routine, utilize polynucleotide sequence of the present invention to can be used to express or produce zinc finger protein KRAZ2-12 (Science, 1984 that the people KRAB of reorganization comprises; 224:1431).In general following steps are arranged:

(1). the polynucleotide (or varient) of the zinc finger protein KRAZ2-12 that comprises with everybody KRAB of coding of the present invention, or transform or the transduction proper host cell with the recombinant expression vector that contains these polynucleotide;

(2). in suitable medium, cultivate host cell;

(3). separation, protein purification from substratum or cell.

In step (2), according to used host cell, used substratum can be selected from various conventional substratum in the cultivation.Under the condition that is suitable for the host cell growth, cultivate.After host cell grows into suitable cell density, induce the promotor of selection with suitable method (as temperature transition or chemical induction), cell is cultivated for some time again.

In step (3), recombinant polypeptide can wrap and be expressed or be secreted into the extracellular in cell or on cytolemma.If desired, can utilize its physics, the separating by various separation methods with other characteristic and the albumen of purification of Recombinant of chemistry.These methods are well-known to those skilled in the art.These methods include, but are not limited to: conventional renaturation is handled, protein precipitant is handled (salt analysis method), centrifugal, the broken bacterium of infiltration, the combination of ultrasonication, super centrifugal, sieve chromatography (gel-filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography (LC) technology and these methods.

The antagonist of polypeptide of the present invention and this polypeptide, agonist and inhibitor can be directly used in disease treatment, for example, can treat malignant tumour, adrenal gland defect, tetter, all kinds of inflammation, HIV infection and immunological disease etc.

Zinc finger protein family is many to participate in transcriptional regulatory by combining with DNA.C2H2 type zinc finger protein comprises the Kruppel zinc finger protein of specificity structure.The Kruppel type zinc finger protein that contains the KRAB structural domain has constituted a class subfamily, and the KRAB structural domain is relevant with proteic correct location and performance function.The zinc finger protein KRAZ2 that comprises the KRAB box has the adjusting transcriptional activity equally, and the repressor activity is mediated by corepressor KAP-1, KRAZ1/2 can be attached to KAP-1, and product can not react with KAP-1 but the KRAB of KRAZ1/2 suddenlys change, and causes checking active lacking.KAP-1 has the activity that checks in essence, has promoted checking of KRAB1/2 mediation.Transcribe in vivo in the experiment, except activation was transcribed, KRAB can also check basic promotion factor active.

Discover, it is relevant with following disease that some contain the albumen of C2H2 type Zinc finger domain: blood malignant disease such as leukemia, non_hodgkin lymphoma, solid tumor such as thyroid adenoma, hysteromyoma, nervous system disorders such as extrapyramidal system dysfunction, parkinson's syndrome, ataxia, neurocytoma, glioma, grow disorders such as Williams syndromes, ulcuscuris, shellfish syndrome Weis two, other tumour such as neuroblastoma, colorectal carcinoma, mammary cancer or the like.

Polypeptide of the present invention and the zinc finger protein KRAZ2 height homology that comprises the KRAB box, both are all the member of Novel Human Zinc Finger Protein KRAB subfamily and have similar physiologic function.

This shows that the abnormal expression of the zinc finger protein KRAZ2-12 that people KRAB of the present invention comprises will produce the especially various tumours of various diseases, nervous system disorders, blood malignant disease, grow disorders, these diseases include but not limited to:

The tumour of various tissues: thyroid tumor, hysteromyoma, neuroblastoma, ependymoma, colorectal carcinoma, mammary cancer, leukemia, lymphoma, malignant histocytosis, melanoma, sarcoma, cancer of the stomach, liver cancer, lung cancer, the esophageal carcinoma, myelomatosis, teratoma, adrenal carcinoma, bladder cancer, osteocarcinoma, osteosarcoma, the cancer of the brain, uterus carcinoma, carcinoma of gallbladder, liver cancer, thymus neoplasms, hysteromyoma, astrocytoma, ependymoma, glioma, neurofibroma, colorectal carcinoma, myelomatosis, bone marrow cancer, carcinoma of endometrium, carcinoma of gallbladder, nasal cavity and tumor of sinus of nose, nasopharyngeal carcinoma, laryngocarcinoma, tracheal neoplasm, fibroma, fibrosarcoma, lipoma, liposarcoma, leiomyoma

Grow disorder disease: extrapyramidal system dysfunction, monster, Williams syndromes, Alagille syndromes, cleft hand are split pedopathy and shellfish syndrome Weis two, congenital miscarriage, cleft palate, deficiency of skeletal limb, limbs dysdifferentiation, hyaline membrane disease, atelectasis, polycystic kidney, cryptorchidism, congenital inguinal hernia, duplex uterus, vaginal atresia, hypospadia, hermaphroditism, atrial septal defect, ventricular septal defect, pulmonic stenosis, patent ductus arteriosus, neural tube defect, congenital hydrocephalus, iridocoloboma, congenital glaucoma or cataract, congenital deafness

Nervous system disorders: parkinson's syndrome, ataxia, neurocytoma, glioma, senile dementia, dysthymia disorders, amnesia, Heng Yandun disease, epilepsy, migraine, dementia, multiple sclerosis, myasthenia gravis, the false hypertrophy of flesh, myotonic dystrophy, myodystonia, schizophrenia, dysthymia disorders, paranoia, anxiety disorder, obsession, phobia, neural decline

Blood malignant disease: leukemia, non_hodgkin lymphoma

The abnormal expression of the zinc finger protein KRAZ2-12 that people KRAB of the present invention comprises also will produce some heredopathia, endocrine system disease such as endocrine neoplasia, disease of immune system.

The antagonist of polypeptide of the present invention and this polypeptide, agonist and inhibitor can be directly used in disease treatment, for example, can treat the especially various tumours of various diseases, nervous system disorders, growth disorders, blood malignant disease, some heredopathia, endocrine system disease such as endocrine neoplasia, disease of immune system etc.

The present invention also provides SCREENED COMPOUND to identify the method that improves (agonist) or check the medicament of the zinc finger protein KRAZ2-12 that (antagonist) people KRAB comprises.Agonist improves zinc finger protein KRAZ2-12 that people KRAB comprises biological function such as stimulate cellular proliferation, and antagonist prevention disorder such as the various cancer relevant with cell hyperproliferation with treatment.For example, can be in the presence of medicine, the film preparation of the zinc finger protein KRAZ2-12 that mammalian cell or expressing human KRAB are comprised is cultivated with the zinc finger protein KRAZ2-12 that the people KRAB of mark comprises.Measure the medicine raising then or check this interactional ability.

The antagonist of the zinc finger protein KRAZ2-12 that people KRAB comprises comprises antibody, compound, acceptor disappearance thing and the analogue etc. that filter out.The antagonist of the zinc finger protein KRAZ2-12 that people KRAB comprises can combine and eliminate its function with the zinc finger protein KRAZ2-12 that people KRAB comprises, or suppress the generation of this polypeptide, or combine with the avtive spot of this polypeptide and to make this polypeptide can not bring into play biological function.

In screening during as the compound of antagonist, the zinc finger protein KRAZ2-12 that people KRAB can be comprised adds during bioanalysis measures, and determines by measuring between zinc finger protein KRAZ2-12 that compound comprises people KRAB and its acceptor interactional influence whether compound is antagonist.With the same quadrat method of above-mentioned SCREENED COMPOUND, can filter out the acceptor disappearance thing and the analogue of antagonist action.The zinc finger protein KRAZ2-12 bonded peptide molecule that can comprise with people KRAB can be incorporated into the rondom polypeptide storehouse that solid formation forms by the various amino acid that may make up by screening and obtain.During screening, generally tackle the zinc finger protein KRAZ2-12 molecule that people KRAB comprises and carry out mark.

The invention provides and use polypeptide, and fragment, derivative, analogue or their cell are as the method for antigen with production antibody.These antibody can be polyclonal antibody or monoclonal antibody.The present invention also provides the antibody of the zinc finger protein KRAZ2-12 antigenic determinant that comprises at people KRAB.These antibody include, but is not limited to: the fragment that polyclonal antibody, monoclonal antibody, chimeric antibody, single-chain antibody, Fab fragment and Fab expression library produce.

Can the choose method of the zinc finger protein KRAZ2-12 direct injection immune animal (as rabbit, mouse, rat etc.) that KRAB comprises of the production of polyclonal antibody obtains, and multiple adjuvant can be used for the enhancing immunity reaction, includes but not limited to freund's adjuvant etc.The technology of the monoclonal antibody of the zinc finger protein KRAZ2-12 that preparation people KRAB comprises includes but not limited to hybridoma technology (Kohler and Milstein.Nature, 1975,256:495-497), three knurl technology, people B-quadroma technology, EBV-hybridoma technology etc.With the variable region bonded chimeric antibody in human constant region and inhuman source can with existing technology production (Morrison etal, PNAS, 1985,81:6851).And the technology of existing manufacture order chain antibody (U.S.Pat No.4946778) also can be used for producing the single-chain antibody of the zinc finger protein KRAZ2-12 that anti-people KRAB comprises.

The antibody of the zinc finger protein KRAZ2-12 that anti-people KRAB comprises can be used in the immunohistochemistry technology, detects the zinc finger protein KRAZ2-12 that the people KRAB in the biopsy specimen comprises.

The also available labelled with radioisotope of zinc finger protein KRAZ2-12 bonded monoclonal antibody with people KRAB comprises injects in the body and can follow the tracks of its position and distribution.This radiolabeled antibody can be used as a kind of atraumatic diagnostic method and is used for the location of tumour cell and has judged whether transfer.

Antibody also can be used for designing the immunotoxin at a certain privileged sites in the body.The monoclonal antibody of the zinc finger protein KRAZ2-12 high-affinity that comprises as people KRAB can with bacterium or plant poison (as diphtheria toxin, ricin, abrine etc.) covalent attachment.A kind of usual method is with sulfydryl linking agent such as SPDP, attacks the amino of antibody, by the exchange of disulfide linkage, toxin is incorporated on the antibody, and this hybrid antibody can be used for killing the zinc finger protein KRAZ2-12 positive cells that people KRAB comprises.

The relevant disease of zinc finger protein KRAZ2-12 that antibody among the present invention can be used for treating or prevention and people KRAB comprise.The antibody that gives suitable dosage can stimulate or block generation or the activity of the zinc finger protein KRAZ2-12 that people KRAB comprises.

The invention still further relates to diagnostic testing process quantitative and the zinc finger protein KRAZ2-12 level that detection and localization people KRAB comprises.These tests are known in the art, and comprise that FISH measures and radioimmunoassay.The zinc finger protein KRAZ2-12 level that the people KRAB that is detected in the test comprises, the disease that the importance of zinc finger protein KRAZ2-12 in various diseases that can comprise with the people KRAB that lays down a definition and the zinc finger protein KRAZ2-12 that is used to diagnose people KRAB to comprise work.

Polypeptide of the present invention also can be used as the peptide spectrum analysis, for example, the polypeptide available physical, chemistry or enzyme carry out the specificity cutting, and carries out the two-dimentional or three-dimensional gel electrophoresis analysis of one dimension, be more preferably and carry out mass spectroscopy.

The polynucleotide of the zinc finger protein KRAZ2-12 that coding people KRAB comprises also can be used for multiple therapeutic purpose.Gene therapy technology can be used for treating because cell proliferation, growth or the metabolic disturbance due to the nothing expression of the zinc finger protein KRAZ2-12 that people KRAB comprises or the unusual/non-activity expression.The gene therapy vector (as virus vector) of reorganization can be designed for the zinc finger protein KRAZ2-12 that the people KRAB that expresses variation comprises, to suppress the zinc finger protein KRAZ2-12 activity that endogenic people KRAB comprises.For example, the zinc finger protein KRAZ2-12 that a kind of people KRAB of variation comprises can be the zinc finger protein KRAZ2-12 that people KRAB shortening, that lacked signal conduction function territory comprises, though can combine with the substrate in downstream, lacks signaling activity.Therefore the gene therapy vector of reorganization can be used for treating that zinc finger protein KRAZ2-12 that people KRAB comprises expresses or the disease of active caused by abnormal.Deriving from the polynucleotide that the expression vector of virus such as retrovirus, adenovirus, adeno-associated virus (AAV), hsv, parvovirus etc. can be used for zinc finger protein KRAZ2-12 that coding people KRAB is comprised is transferred in the cell.The method of recombinant viral vector that structure carries the polynucleotide of the zinc finger protein KRAZ2-12 that coding people KRAB comprises is found in existing document (Sambrook, et al.).The polynucleotide of the zinc finger protein KRAZ2-12 that the coding people KRAB that recombinates in addition comprises can be packaged in the liposome and be transferred in the cell.

Polynucleotide import tissue or intracellular method comprises: directly be injected into polynucleotide in the in-vivo tissue; Or external by carrier (as virus, phage or plasmid etc.) earlier with the polynucleotide transfered cell in, again cell is transplanted in the body etc.

Suppress the oligonucleotide (comprising sense-rna and DNA) of the zinc finger protein KRAZ2-12mRNA that people KRAB comprises and ribozyme also within the scope of the invention.Ribozyme is the enzyme sample RNA molecule that a kind of energy specificity is decomposed specific RNA, and its mechanism of action is to carry out the endonuclease effect after ribozyme molecule and the hybridization of complementary target RNA-specific.The RNA of antisense and DNA and ribozyme can obtain with existing any RNA or DNA synthetic technology, as the technology widespread use of solid phase phosphoamide chemical synthesis synthetic oligonucleotide.Antisense rna molecule can be transcribed acquisition by the dna sequence dna of this RNA that encodes in external or body.This dna sequence dna has been incorporated into the downstream of rna polymerase promoter of carrier.In order to increase the stability of nucleic acid molecule, available several different methods is modified it, and as increasing the sequence length of both sides, the connection between the ribonucleoside is used phosphoric acid thioester bond or peptide bond but not phosphodiester bond.

The polynucleotide of the zinc finger protein KRAZ2-12 that coding people KRAB comprises can be used for the diagnosis of the relative disease of the zinc finger protein KRAZ2-12 that comprises with people KRAB.Whether or the unconventionality expression of the zinc finger protein KRAZ2-12 that people KRAB comprises under morbid state the expression that the polynucleotide of the zinc finger protein KRAZ2-12 that coding people KRAB comprises can be used for detecting the zinc finger protein KRAZ2-12 that people KRAB comprises.As the dna sequence dna of the zinc finger protein KRAZ2-12 that comprises of the people KRAB that encodes can be used for biopsy specimen is hybridized to judge the expression situation of the zinc finger protein KRAZ2-12 that people KRAB comprises.Hybridization technique comprises the Southern blotting, Northern blotting, in situ hybridization etc.These technological methods all are disclosed mature technologies, and relevant test kit all can obtain from commercial channels.Part or all of polynucleotide of the present invention can be used as probe stationary on microarray (Microarray) or DNA chip (being called " gene chip " again), is used for analyzing the differential expression analysis and the gene diagnosis of tissue gene.The special primer of zinc finger protein KRAZ2-12 that comprises of personnel selection KRAB carries out the transcription product that RNA-polymerase chain reaction (RT-PCR) amplification in vitro also can detect the zinc finger protein KRAZ2-12 that people KRAB comprises.

The sudden change that detects the zinc finger protein KRAZ2-12 gene that people KRAB comprises also can be used for the relevant disease of zinc finger protein KRAZ2-12 of diagnosing people KRAB to comprise.The form of zinc finger protein KRAZ2-12 that people KRAB comprises sudden change comprises that point mutation that the zinc finger protein KRAZ2-12DNA sequence that comprises with normal wild type people KRAB compares, transposition, disappearance, reorganization and other are any unusual etc.Available existing technology such as Southern blotting, dna sequence analysis, PCR and in situ hybridization detect sudden change.In addition, sudden change might influence proteic expression, therefore can judge indirectly that with Northern blotting, Western blotting gene has or not sudden change.

Sequence of the present invention identifies it also is valuable to karyomit(e).This sequence can be specifically at certain bar human chromosome particular location and and can with its hybridization.At present, need to identify the concrete site of each gene on the karyomit(e).Now, have only chromosomal marker thing seldom to can be used for the marker chromosomes position based on actual sequence data (repetition polymorphism).According to the present invention, for these sequences are associated with disease related gene, its important the first step is positioned these dna sequence dnas on the karyomit(e) exactly.

In brief, prepare PCR primer (preferred 15-35bp), sequence can be positioned on the karyomit(e) according to cDNA.Then, these primers are used for the somatocyte hybrid cell that the PCR screening contains each bar human chromosome.Have only those hybrid cells that contain corresponding to the people's gene of primer can produce the fragment of amplification.

The PCR localization method of somatocyte hybrid cell is that DNA is navigated to concrete chromosomal quick method.Use Oligonucleolide primers of the present invention,, can utilize one group to realize inferior location from specific chromosomal fragment or a large amount of genomic clone by similar approach.Other the similar strategy that can be used for chromosomal localization comprises in situ hybridization, uses the karyomit(e) prescreen and the hybridization preliminary election of the airflow classification of mark, thereby makes up the special cDNA storehouse of karyomit(e).

The cDNA clone is carried out fluorescence in situ hybridization (FISH) with Metaphase Chromosome, can in a step, accurately carry out chromosomal localization.The summary of this technology is referring to Verma etc., Human Chromosomes:a Manualof Basic Techniques, Pergamon Press, New York (1988).

In case sequence is positioned to chromosome position accurately, the physical location of this sequence on karyomit(e) just can be associated with the gene map data.These data for example are found in, V.Mckusick, MendelianInheritance in Man (can by with the online acquisition of Johns Hopkins University Welch Medical Library).Can pass through linkage analysis then, determine gene and navigated to relation between the disease on the chromosomal region already.

Then, need to measure ill and not cDNA between diseased individuals or genome sequence difference.If observe certain sudden change in some or all of diseased individuals, and this sudden change is not observed in any normal individual, then this sudden change may be the cause of disease of disease.More ill and diseased individuals not is usually directed at first seek the variation of structure in the karyomit(e), as from the horizontal visible of karyomit(e) or use based on detectable disappearance of the PCR of cDNA sequence or transposition.Resolving power according to present physical mapping and assignment of genes gene mapping technology, being accurately positioned to the cDNA of the chromosomal region relevant with disease, can be a kind of (the supposing that 1 megabasse mapping resolving power and every 20kb are corresponding to a gene) between 50 to 500 potential Disease-causing genes.

Polypeptide of the present invention, polynucleotide and stand-in thereof, agonist, antagonist and inhibitor and suitable pharmaceutical carrier combination back can be used.These carriers can be water, glucose, ethanol, salt, damping fluid, glycerine and their combination.Composition comprises the polypeptide or the antagonist of safe and effective amount and carrier and the vehicle that does not influence effect of drugs.These compositions can be used as medicine and are used for disease treatment.

The present invention also provides medicine box or the test kit that contains one or more containers, and one or more medicinal compositions compositions of the present invention are housed in the container.With these containers, can have by the given indicative prompting of government authorities of making, using or selling medicine or biological products, the government authorities that this prompting reflects production, uses or sells permits it to use on human body.In addition, polypeptide of the present invention can be used in combination with other treatment compound.

Pharmaceutical composition can be with mode administration easily, as by in part, intravenously, intraperitoneal, intramuscular, subcutaneous, the nose or the route of administration of intracutaneous.The zinc finger protein KRAZ2-12 that people KRAB comprises comes administration with the amount that treats and/or prevents concrete indication effectively.The amount and the dosage range that are applied to the zinc finger protein KRAZ2-12 that patient's people KRAB comprises will depend on many factors, as administering mode, person's to be treated healthiness condition and diagnostician's judgement.

Following accompanying drawing is used to illustrate specific embodiments of the present invention, and is not used in qualification by the scope of the invention that claims defined.

Fig. 1 is the zinc finger protein KRAZ2-12 that comprises of inventor KRAB and the amino acid sequence homology comparison diagram of KRAZ2.The top sequence is the zinc finger protein KRAZ2-12 that people KRAB comprises, and the below sequence is KRAZ2.Same amino acid represents with monocase amino acid that between two sequences similar amino acid is represented with "+".

The polyacrylamide gel electrophoresis figure (SDS-PAGE) of the zinc finger protein KRAZ2-12 that Fig. 2 comprises for isolating people KRAB.12KDa is proteinic molecular weight.The arrow indication is isolated protein band.

Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to people such as normal condition such as Sambrook, molecular cloning: laboratory manual (New York:ColdSpring Harbor Laboratory Press, 1989) condition described in, or the condition of advising according to manufacturer.Embodiment 1: the clone of the zinc finger protein KRAZ2-12 that people KRAB comprises

Extract the total RNA of people's tire brain with guanidinium isothiocyanate/phenol/chloroform single stage method.From total RNA, separate poly (A) mRNA with Quik mRNA Isolation Kit (Qiegene company product).2ug poly (A) mRNA forms cDNA through reverse transcription.CDNA fragment orientation is inserted on the multiple clone site of pBSK (+) carrier (Clontech company product) with Smart cDNA clone's test kit (available from Clontech), transforms DH5 α, bacterium forms the cDNA library.Measure all clones' 5 ' and 3 ' terminal sequence with Dyeterminate cycle reaction sequencing kit (Perkin-Elmer company product) and ABI377 automatic sequencer (Perkin-Elmer company).CDNA sequence and the existing public dna sequence data storehouse (Genebank) measured are compared, found that the cDNA sequence of one of them clone 1473e06 is new DNA.By synthetic a series of primers the contained insertion cDNA fragment of this clone is carried out two-way mensuration.The result shows, the contained full-length cDNA of 1473e06 clone is 1050bp (shown in Seq ID NO:1), from 39bp to 362bp the open reading frame (ORF) of a 324bp, the new protein (shown in SeqID NO:2) of encoding arranged.We are with this clone's called after pBS-1473e06, the zinc finger protein KRAZ2-12 that the name of encoded protein matter comprises for people KRAB.Embodiment 2:cDNA clone's homology retrieval

Sequence and the encoded protein sequence thereof of the zinc finger protein KRAZ2-12 that people KRAB of the present invention is comprised are with Blast program (Basiclocal Alignment search tool) [Altschul, SF et al.J.Mol.Biol.1990; 215:403-10], carry out the homology retrieval at databases such as Genbank, Swissport.The gene that the zinc finger protein KRAZ2-12 homology that comprises with people KRAB of the present invention is the highest is a kind of known KRAZ2, and its encoded protein number is AB024005 in the access of Genbank.Protein homology the results are shown in Fig. 1, both height homologies, and its homogeny is 71%; Similarity is 84%.Embodiment 3: the gene of the zinc finger protein KRAZ2-12 that comprises with RT-PCR method clones coding people KRAB

Total RNA is a template with fetus brain cell, is that primer carries out the synthetic cDNA of reverse transcription reaction with oligo-dT, with behind the test kit purifying of Qiagene, carries out pcr amplification with following primer:

Primer1:5’-ACGTGGATGATGCTTAGAGGACCC-3’(SEQ?ID?NO:3)

Primer2:5’-CATAGGCCGAGGCGGCCGACATGT-3’(SEQ?ID?NO:4)

Primer1 is the forward sequence that begins of 1bp that is positioned at the 5 ' end of SEQ ID NO:1;

Primer2 be SEQ ID NO:1 in 3 ' end reverse sequence.

The condition of amplified reaction: in the reaction volume of 50 μ l, contain 50mmol/L KCl, 10mmol/L Tris-Cl, (pH8.5), 1.5mmol/L MgCl ₂, 200 μ mol/L dNTP, 10pmol primer, the Taq archaeal dna polymerase of 1U (Clontech company product).Go up by 25 cycles of following conditioned response at PE9600 type DNA thermal cycler (Perkin-Elmer company): 94 ℃ of 30sec; 55 ℃ of 30sec; 72 ℃ of 2min.When RT-PCR, establish the blank negative contrast of positive contrast of β-actin and template simultaneously.Amplified production is connected to (Invitrogen company product) on the pCR carrier with the test kit purifying of QIAGEN company with TA clone test kit.The dna sequence analysis result shows that the dna sequence dna of PCR product and the 1-1050bp shown in the SEQ ID NO:1 are identical.The zinc finger protein KRAZ2-12 expression of gene that embodiment 4:Northern blotting analyst KRAB comprises:

Extract total RNA[Anal.Biochem 1987,162,156-159 with single stage method].This method comprises acid guanidine thiocyanate phenol-chloroform extracting.Promptly use 4M guanidinium isothiocyanate-25mM Trisodium Citrate, 0.2M sodium acetate (pH4.0) carries out homogenate to tissue, adds the phenol of 1 times of volume and the chloroform-primary isoamyl alcohol (49: 1) of 1/5 volume, and is centrifugal after mixing.The sucking-off aqueous phase layer adds Virahol (0.8 volume) and with the centrifugal RNA precipitation that obtains of mixture.With RNA precipitation 70% washing with alcohol that obtains, dry and soluble in water.With 20 μ g RNA, on 1.2% sepharose that contains 20mM 3-(N-morpholino) propanesulfonic acid (pH7.0)-5mM sodium acetate-1mM EDTA-2.2M formaldehyde, carry out electrophoresis.Be transferred on the nitrocellulose filter then.With α- ³²P dATP prepares by random priming ³²The dna probe of P-mark.Used dna probe is the zinc finger protein KRAZ2-12 coding region sequence (39bp to 362bp) that the people KRAB of pcr amplification shown in Figure 1 comprises.Probe (about 2 * 10 with the 32P-mark ⁶Cpm/ml) spend the night in 42 ℃ of hybridization in a solution with the nitrocellulose filter that has shifted RNA, this solution comprises 50% methane amide-25mM KH ₂PO ₄(pH7.4)-5 * SSC-5 * Denhardt ' s solution and 200 μ g/ml salmon sperm DNAs.After the hybridization, filter membrane is washed 30min in 55 ℃ in 1 * SSC-0.1%SDS.Then, analyze with quantitative with Phosphor Imager.Embodiment 5: vivoexpression, separation and the purifying of the zinc finger protein KRAZ2-12 that recombinant human KRAB comprises

According to SEQ ID NO:1 and coding region sequence shown in Figure 1, design a pair of specificity amplification primer, sequence is as follows:

Primer3:5’-CCCCATATGATGCTGGAGACCTACAACAGCCTG-3’(Seq?ID?No:5)

Primer4:5’-CATGGATCCTCAAACCTCCTGGAGCTCCACCAG-3’(Seq?ID?No:6)

5 ' end of these two sections primers contains Nde I and BamH I restriction enzyme site respectively, be respectively the encoding sequence of target gene 5 ' end and 3 ' end thereafter, Nde I and BamH I restriction enzyme site are corresponding to expression vector plasmid pET-28b (+) (Novagen company product, Cat.No.69865.3) the selectivity restriction enzyme site on.With the pBS-1473e06 plasmid that contains the total length goal gene is template, carries out the PCR reaction.The PCR reaction conditions is: contain pBS-1473e06 plasmid 10pg, primer Primer-3 and Primer-4 among the cumulative volume 50 μ l and be respectively 10pmol, Advantage polymerase Mix (Clontech company product) 1 μ l.Loop parameter: 94 ℃ of 20s, 60 ℃ of 30s, 68 ℃ of 2min, totally 25 circulations.Respectively amplified production and plasmid pET-28 (+) are carried out double digestion with Nde I and BamH I, reclaim big fragment respectively, and connect with the T4 ligase enzyme.Connect product and transform, after the dull and stereotyped overnight incubation of the LB that contains kantlex (final concentration 30 μ g/ml), use the colony polymerase chain reaction (PCR) method screening positive clone, and check order with the big enterobacterial DH5 of Calcium Chloride Method α.Select the correct positive colony of sequence (pET-1473e06) with Calcium Chloride Method with recombinant plasmid transformed e. coli bl21 (DE3) plySs (Novagen company product).In the LB liquid nutrient medium that contains kantlex (final concentration 30 μ g/ml), host bacterium BL21 (pET-1473e06) is cultured to logarithmic phase at 37 ℃, adds IPTG to final concentration 1mmol/L, continues to cultivate 5 hours.Centrifugal collection thalline, through the broken bacterium of ultrasonic wave, centrifugal collection supernatant, with carrying out chromatography, obtained the zinc finger protein KRAZ2-12 that the target protein people KRAB of purifying comprises with 6 Histidines (6His-Tag) bonded affinity column His.Bind Quick Cartridge (Novagen company product).Through the SDS-PAGE electrophoresis, obtain a single band (Fig. 2) at the 12KDa place.This band is transferred on the pvdf membrane carries out the n terminal amino acid sequential analysis with the Edams hydrolysis method, 15 amino acid of N-end hold 15 amino-acid residues identical with the N-shown in the SEQ ID NO:2 as a result.The zinc finger protein KRAZ2-12 production of antibodies that embodiment 6 anti-people KRAB comprise

Synthesize the specific polypeptide of zinc finger protein KRAZ2-12 that following people KRAB comprises with Peptide synthesizer (PE company product):

NH2-Met-Leu-Glu-Thr-Tyr-Asn-Ser-Leu-Val-Ser-Leu-Gln-Glu-Leu-Val-COOH(SEQ?ID?NO:7)。Form compoundly with hemocyanin and bovine serum albumin coupling this polypeptide respectively, method is referring to Avrameas, et al.Immunochemistry, 1969; 6:43.Add the complete Freund's adjuvant immunizing rabbit with the above-mentioned hemocyanin polypeptide complex of 4mg, add the incomplete Freund's adjuvant booster immunization once with the hemocyanin polypeptide complex again after 15 days.Employing is done the titre that ELISA measures antibody in the rabbit anteserum through the titer plate of 15 μ g/ml bovine serum albumin polypeptide complex bag quilts.From the rabbit anteserum of antibody positive, separate total IgG with albumin A-Sepharose.Polypeptide is incorporated on the Sepharose4B post of cyanogen bromide-activated, from total IgG, separates anti-peptide antibody with affinity chromatography.Immuno-precipitation proof antibody purified can combine with the zinc finger protein KRAZ2-12 that people KRAB comprises specifically.Embodiment 7: polynucleotide passage of the present invention is as the application of hybridization probe

Picking out suitable oligonucleotide fragment from polynucleotide of the present invention is of use in many ways as hybridization probe, as can whether containing polynucleotide sequence of the present invention and detect the homologous polynucleotide sequence to identify it with the healthy tissues of different sources or the genome or the hybridization of cDNA library of pathological tissue with this probe, whether further also available this probe in detecting polynucleotide sequence of the present invention or the expression of its homologous polynucleotide sequence in healthy tissues or pathological tissue cell be unusual.

The purpose of present embodiment is to pick out suitable oligonucleotide fragment as hybridization probe from polynucleotide SEQ ID NO:1 of the present invention, and identifies in some tissues whether contain polynucleotide sequence of the present invention or its homologous polynucleotide sequence with the filter hybridization method.The filter hybridization method comprises dot blotting, Southern blotting, Northern blotting and copy method etc., and they all are that polynucleotide sample to be measured is fixed on use essentially identical step crossover in back on the filter membrane.These identical steps are: the filter membrane of having fixed sample at first carries out prehybridization with the hybridization buffer that does not contain probe, so that nonspecific combining site suppressed by vector of sample and synthetic polymer institute are saturated on the filter membrane.Prehybridization solution is contained the hybridization buffer replacement of label probe then, and insulation makes probe and target nucleic acid hybridization.After the hybridization step, the probe in the hybridization is not removed by a series of film steps of washing.Present embodiment utilizes the film condition of washing (as than low salt concn and higher temperature) of higher-strength, so that hybrid context reduces and only keep the signal of high specificity.The probe that present embodiment is selected for use comprises two classes: first kind probe be fully with the identical or complementary oligonucleotide fragment of polynucleotide SEQ ID NO:1 of the present invention; The second class probe is part and the identical or complementary oligonucleotide fragment of polynucleotide SEQ ID NO:1 of the present invention.Present embodiment selects for use dot blotting that sample is fixed on the filter membrane, higher-strength wash under the film condition, the hybridization specificity of first kind probe and sample is the strongest and kept.One, probe selects for use

From polynucleotide SEQ ID NO:1 of the present invention, select oligonucleotide fragment as hybridization probe, the several aspects that should follow following principle and need to consider: 1, the probe size preferable range is a 18-50 Nucleotide; 2, GC content is 30%-70%, and surpassing then, non-specific hybridization increases; 3, probe interior should not have complementary region; 4, what meet above condition can be used as the primary election probe, further do the computer sequential analysis then, comprise this primary election probe is carried out homology relatively with its source sequence area (being SEQ ID NO:1) and other known genome sequence and complementary district thereof respectively, if with the homology in non-target molecule zone greater than 85% or there are 15 continuous bases of surpassing identical, then this primary election probe is general just should not use; 5, whether the primary election probe finally is chosen to be the probe of actual application value also should further be determined by experiment.

Select and synthetic following two probes after finishing the analysis of above each side:

Probe 1 (probel) belongs to first kind probe, and complete homology of gene fragment or the complementation (41Nt) of SEQ ID NO:1:

5’-TGCTGGAGACCTACAACAGCCTGGTATCATTACAGGAGTTG-3’(SEQ?ID?NO:8)

Probe 2 (probe2) belongs to the second class probe, is equivalent to gene fragment or its complementary segmental replacement mutant nucleotide sequence (41Nt) of SEQ ID NO:1:

5’-TGCTGGAGACCTACAACAGCCTGGTATCATTACAGGAGTTG-3’(SEQ?ID?NO:9)

Other unlisted common agents and the compound method thereof relevant with following concrete experimental procedure please refer to document: DNA PROBES G.H.Keller; M.M.Manak; Stockton Press, 1989 (USA) and molecular cloning laboratory manual books more commonly used are as works such as " molecular cloning experiment guide " (second edition in 1998) [U.S.] Sa nurse Brooker, Science Press.

Specimen preparation: 1, from fresh or frozen tissue, extract DNA

Step: 1) the fresh or fresh normal liver tissue that thaws is put into the plate that is immersed on ice and fills phosphate buffered saline buffer (PBS).With scissors or scalpel tissue is cut into small pieces.Should keep organizing moistening in the operation.2) with 1000g centrifugal chopper tissue 10 minutes.3) with cooled homogenate damping fluid (0.25mol/L sucrose; 25mmol/LTris-HCl, pH7.5; 25mmol/LnaCl; 25mmol/L MgCl ₂) precipitation that suspends (approximately 10ml/g).4) 4 ℃ with electric homogenizer homogenate tissue suspension at full speed, until tissue by broken fully.5) 1000g is centrifugal 10 minutes.6) with re-suspended cell precipitation (the initial tissue sample of every 0.1g adds 1-5ml), centrifugal 10 minutes again with 1000g.7) with the resuspended precipitation of lysis buffer (the initial tissue sample of every 0.1g adds 1ml), connect following phenol extraction process then.2, the phenol extraction process of DNA

Step: 1) wash cell, centrifugal 10 minutes of 1000g with the cold PBS of 1-10ml.2) with the sedimentary cell (1 * 10 of cold cell pyrolysis liquid resuspension ⁸The minimum of applications 100ul lysis buffer of cell/ml).3) adding SDS is 1% to final concentration, if before re-suspended cell SDS is directly joined in the cell precipitation, cell may form big agglomerate and be difficult to fragmentation, and the overall yield that reduces.This point is in extracting＞10 ⁷Especially severe during cell.4) add Proteinase K to final concentration 200ug/ml.5) 50 ℃ of insulation reaction 1 hour or 37 ℃ gently jolting spend the night.6) use equal-volume phenol: chloroform: primary isoamyl alcohol (25: 24: 1) extracting, in little centrifuge tube centrifugal 10 minutes.Two corresponding clear separation, otherwise carry out centrifugal again.7) water is transferred to new pipe.8) use the equal-volume chloroform: primary isoamyl alcohol (24: 1) extracting, centrifugal 10 minutes.9) water that will contain DNA is transferred to new pipe.Carry out purifying and the ethanol sedimentation of DNA then.3, the purifying of DNA and ethanol sedimentation

Step: 1) 1/10 volume 2mol/L sodium-acetate and 2 times of cold 100% ethanol of volume are added in the dna solution mixing.-20 ℃ of placements 1 hour or to spending the night.2) centrifugal 10 minutes.3) careful sucking-off or pour out ethanol.4) with 70% cold ethanol 500ul washing precipitation, centrifugal 5 minutes.5) careful sucking-off or pour out ethanol.With the cold washing with alcohol precipitation of 500ul, centrifugal 5 minutes.6) careful sucking-off or pour out ethanol is inverted on thieving paper then residual ethanol is flow to end.Dry air 10-15 minute, so that the volatilization of surperficial ethanol.Note not making the precipitation complete drying, otherwise dissolve again than difficulty.7) with small volume TE or the resuspended DNA precipitation of water.The low speed vortex vibrates or uses the dropper pressure-vaccum, increases TE gradually simultaneously, is mixed to DNA and fully dissolves, every 1-5 * 10 ⁶Cell extracted approximately adds 1ul.

Below the 8-13 step only be used for must removing when depolluting, otherwise can directly carry out the 14th step.8) RNA enzyme A is added in the dna solution, final concentration is 100ug/ml, and 37 ℃ are incubated 30 minutes.9) add SDS and Proteinase K, final concentration is respectively 0.5% and 100ug/ml.37 ℃ are incubated 30 minutes.10) use isopyknic phenol: chloroform: primary isoamyl alcohol (25: 24: 1) extractive reaction liquid, centrifugal 10 minutes.11) carefully shift out water, use isopyknic chloroform: primary isoamyl alcohol (24: 1) extracting again, centrifugal 10 minutes.12) carefully shift out water, add 1/10 volume 2mol/L sodium-acetate and the cold ethanol of 2.5 volumes, mixing put-20 ℃ 1 hour.13) with 70% ethanol and 100% washing with alcohol precipitation, dry air, resuspended nucleic acid, process is with the 3-6 step.14) measure A ₂₆₀And A ₂₈₀To detect purity and the productive rate of DNA.15) deposit in-20 ℃ after the packing.The preparation of sample film:

1) get 4 * 2 suitably nitrocellulose filters (NC film) of size, mark point sample position and sample number thereon gently with pencil, each probe needs two NC films, so that wash film with high strength condition and strength condition respectively in the experimental procedure of back.

2) draw and contrast respectively 15 microlitres, put on the sample film, dry at room temperature.

3) place infiltration that 0.1mol/LNaOH is arranged, last 5 minute of filter paper (twice) of 1.5mol/LNaCl, drying to place to soak into has 0.5mol/L Tris-HCl (pH7.0), last 5 minute of filter paper (twice) of 3mol/LNaCl, dries.

4) be sandwiched in the clean filter paper, wrap, 60-80 ℃ of vacuum-drying 2 hours with aluminium foil.

The mark of probe

1) 3 μ lProbe (0.10D/10 μ l) add 2 μ lKinase damping fluids, 8-10uCi γ- ³²P-dATP+2UKinase is to add to final volume 20 μ l.

2) 37 ℃ are incubated 2 hours.

3) add the tetrabromophenol sulfonphthalein indicator (BPB) of 1/5 volume.

4) cross Sephadex G-50 post.

5) to having ³²Before washing out, P-Probe begins to collect first peak (available Monitor monitoring).

6) 5/pipe, collect the 10-15 pipe.

7) monitor isotopic weight with liquid glimmer instrument

8) merge and to be required preparation behind the collection liquid of first peak ³²P-Probe (second peak for free γ- ³²P-dATP).

Prehybridization

The sample film is placed plastics bag, and adding 3-10mg prehybridization solution (10 * Denhardt ' s; 6 * SSC, 0.1mg/mlCT DNA (calf thymus DNA).), seal sack after, 68 ℃ of water-baths were shaken 2 hours.

Hybridization

Plastics bag is cut off one jiao, adds the probe prepare, seal sack after, 42 ℃ of water-baths are shaken and are spent the night.

Wash film: high strength is washed film:

1) good sample film has been hybridized in taking-up.

2) 2 * SSC among the 0.1%SDS, washes 15 minutes (2 times) for 40 ℃.

3) 0.1 * SSC among the 0.1%SDS, washes 15 minutes (2 times) for 40 ℃.

4) 0.1 * SSC among the 0.1%SDS, washes 30 minutes (2 times) for 55 ℃, and room temperature is dried.Low strength is washed film:

1) good sample film has been hybridized in taking-up.

2) 2 * SSC among the 0.1%SDS, washes 15 minutes (2 times) for 37 ℃.

3) 0.1 * SSC among the 0.1%SDS, washes 15 minutes (2 times) for 37 ℃.

4) 0.1 * SSC among the 0.1%SDS, washes 15 minutes (2 times) for 40 ℃, and room temperature is dried.

X-light autography:

-70 ℃, X-light autography (the compressing tablet time decides according to hybridization spot radioactivity is strong and weak).

Experimental result:

Adopt low strength to wash the hybrid experiment that the film condition is carried out, more than two strong and weak not obviously differences of probe hybridization spot radioactivity; And adopting high strength to wash the hybrid experiment that the film condition is carried out, the hybridization spot radioactive intensity of probe 1 obviously is better than the radioactive intensity of another probe hybridization spot.Thereby available probe 1 is qualitative and analyze existence and the differential expression of polynucleotide of the present invention in different tissues quantitatively.

Sequence table (1) general information:

(ⅱ) denomination of invention: zinc finger protein KRAZ2-12 and encoding sequence thereof that people KRAB comprises

(ⅲ) sequence number: the information of 9 (2) SEQ ID NO:1:

(ⅰ) sequence signature:

(A) length: 1050bp

(B) type: nucleic acid

(C) chain: two strands

(D) topological framework: linearity

(ⅱ) molecule type: cDNA

( ⅹⅰ ) ：SEQ ID NO:1: 1 ACGTGGATGATGCTTAGAGGACCCTGTACAGGAACGTGATGCTGGAGACCTACAACAGCC 61 TGGTATCATTACAGGAGTTGGTGTCCTTTGAGGAGGTAGCTGTGCACTTCACCTGGGAGG121 AGTGGCAGGACCTGGATGACGCTCAGAGGACCCTGTACAGGGACGTGATGCTGGAGACCT181 ACAGCAGCCTGGTATCATTGGGGCATTGCATTACCAAACCTGAGATGATCTTCAAGCTAG241 AGCAAGGAGCAGAGCCATGGATAGTAGAAGAAACCCTAAACCTGAGACTTTCAGGTGGAA301 GCAAGAAGCAAGTTTTCTCAGGTATTTGCCACAGGAGCCTGGTGGAGCTCCAGGAGGTTT361 GATCTCTCTTGTGAACTCTGGAACTGTATTCCCAATTGTCAATTGGACATCCCTACGTAT421 GGGACCTCAGATATTTCAAACATGATGTGTCCAAGTCTGTATCACTTCTGGCCATCATAT481 TGTTCTTTTATTTTTCCAAATTTCACATCACCAGTAACAAACTAGCTGTGATCATGGCAG541 ATAGCCTGGAAATAAAACTCCCCTTTTTACCCTTTGCACAGCAAATTGACATCAAATCCT601 GTTTCTACTTTTTTTTTTTTTAACTATTGCTTCCCTATTCTGTATTCTCACTGCTCCATC661 TTCTGATGTAGGAGGTCATCTGTTTTCCTCTTTTCCTCTCCTCTGACTCTTAAGCCCTTT721 CCCATTCTCTTTCTCAGGAATGGCTGTTAAAATGCCAATATGGTCTTGTAACTTTCCTGT781 ACTTAGTGAACCTCCTTATTTACACCCTGTTTGTGAAGTGGCTGTGTTCACCCTGGGTGG841 ACACGGAATGTTTTTGGCATGTACAAAGAGAATTTTATGCTGCCTGTGTACAGTTATTAA901 TTTGTAAGTACACTCAGCTTTTTGTATCTGTAGGTTTAATATCTGTGTATGTAAGCAAAC 961 TTGGATGCAAAATATTTGAAATAAAATCAGATGCTTGCATCTGTAGTGAACACAAAAAAA1021 AAAAAAACATGTCGGCCGCCTCGGCCTATG ( 3 ) SEQ ID NO:2：

(ⅰ) sequence signature:

(A) length: 107 amino acid

(B) type: amino acid

(D) topological framework: linearity

(ⅱ) molecule type: polypeptide

(ⅹ ⅰ) sequence description: the information of SEQ ID NO:2:1 Met Leu Glu Thr Tyr Asn Ser Leu Val Ser Leu Gln Glu Leu Val 16 Ser Phe Glu Glu Val Ala Val His Phe Thr Trp Glu Glu Trp Gln 31 Asp Leu Asp Asp Ala Gln Arg Thr Leu Tyr Arg Asp Val Met Leu 46 Glu Thr Tyr Ser Ser Leu Val Ser Leu Gly His Cys Ile Thr Lys 61 Pro Glu Met Ile Phe Lys Leu Glu Gln Gly Ala Glu Pro Trp Ile 76 Val Glu Glu Thr Leu Asn Leu Arg Leu Ser Gly Gly Ser Lys Lys 91 Gln Val Phe Ser Gly Ile Cys His Arg Ser Leu Val Glu Leu Gln106 Glu Val (4) SEQ ID NO:3

(ⅰ) sequence signature

(A) length: 24 bases

(B) type: nucleic acid

(C) chain: strand

(D) topological framework: linearity

(ⅱ) molecule type: oligonucleotide

(ⅹ ⅰ) sequence description: the information of SEQ ID NO:3:ACGTGGATGATGCTTAGAGGACCC 24 (5) SEQ ID NO:4

(ⅰ) sequence signature

(A) length: 24 bases

(B) type: nucleic acid

(C) chain: strand

(D) topological framework: linearity

(ⅱ) molecule type: oligonucleotide

(ⅹ ⅰ) sequence description: the information of SEQ ID NO:4:CATAGGCCGAGGCGGCCGACATGT 24 (6) SEQ ID NO:5

(ⅰ) sequence signature

(A) length: 33 bases

(B) type: nucleic acid

(C) chain: strand

(D) topological framework: linearity

(ⅱ) molecule type: oligonucleotide (ⅹ ⅰ) sequence description: the information of SEQ ID NO:5:CCCCATATGATGCTGGAGACCTACAACAGCCTG 33 (7) SEQ ID NO:6

(ⅰ) sequence signature

(A) length: 33 bases

(B) type: nucleic acid

(C) chain: strand

(D) topological framework: linearity

(ⅱ) molecule type: oligonucleotide (ⅹ ⅰ) sequence description: the information of SEQ ID NO:6:CATGGATCCTCAAACCTCCTGGAGCTCCACCAG 33 (8) SEQ ID NO:7:

(ⅰ) sequence signature:

(A) length: 15 amino acid

(B) type: amino acid

(D) topological framework: linearity

(ⅱ) molecule type: polypeptide (ⅹ ⅰ) sequence description: the information of SEQ ID NO:7:Met-Leu-Glu-Thr-Tyr-Asn-Ser-Leu-Val-Ser-Leu-Gln-Glu-Leu-Val 15 (9) SEQ ID NO:8

(ⅰ) sequence signature

(A) length: 41 bases

(B) type: nucleic acid

(C) chain: strand

(D) topological framework: linearity

(ⅱ) molecule type: oligonucleotide (ⅹ ⅰ) sequence description: the information of SEQ ID NO:8:TGCTGGAGACCTACAACAGCCTGGTATCATTACAGGAGTTG 41 (10) SEQ ID NO:9

(ⅰ) sequence signature

(A) length: 41 bases

(B) type: nucleic acid

(C) chain: strand

(D) topological framework: linearity

(ⅱ) molecule type: oligonucleotide (ⅹ ⅰ) sequence description: SEQ ID NO:9:TGCTGGAGACCTACAACAGCCTGGTATCATTACAGGAGTTG 41

Claims (18)

1, the zinc finger protein KRAZ2-12 that comprises of a kind of isolated polypeptide-people KRAB is characterized in that it includes: the polypeptide of the aminoacid sequence shown in the SEQ ID NO:2 or active fragments, analogue or the derivative of its polypeptide.

2, polypeptide as claimed in claim 1, the aminoacid sequence that it is characterized in that described polypeptide, analogue or derivative has the homogeny with the aminoacid sequence at least 95% shown in the SEQ ID NO:2.

3, polypeptide as claimed in claim 2 is characterized in that it comprises the polypeptide with the aminoacid sequence shown in the SEQ ID NO:2.

4, a kind of isolating polynucleotide, it is characterized in that described polynucleotide comprise be selected from down the group in a kind of:

(a) coding has the polynucleotide of the polypeptide of aminoacid sequence shown in the SEQ ID NO:2 or its fragment, analogue, derivative;

(b) with polynucleotide (a) complementary polynucleotide; Or

(c) with (a) or the polynucleotide of at least 72% homogeny (b) are arranged.

5, polynucleotide as claimed in claim 4 is characterized in that described polynucleotide comprise the polynucleotide that coding has aminoacid sequence shown in the SEQID NO:2.

6, polynucleotide as claimed in claim 4, the sequence that it is characterized in that described polynucleotide include the sequence of 1-1050 position among the sequence of 39-362 position among the SEQ IDNO:1 or the SEQ ID NO:1.

7, a kind of recombinant vectors that contains exogenous polynucleotide is characterized in that it is the recombinant vectors that is formed by the described polynucleotide of arbitrary claim among the claim 4-6 and plasmid, virus or vehicle expression vector establishment.

8, a kind of genetically engineered host cell that contains exogenous polynucleotide is characterized in that it is to be selected from following a kind of host cell:

(a) host cell that transforms or transduce with the described recombinant vectors of claim 7; Or

(b) host cell that transforms or transduce with the described polynucleotide of the arbitrary claim among the claim 4-6.

9, the preparation method of the active polypeptide of zinc finger protein KRAZ2-12 that comprises of a kind of people of having KRAB is characterized in that described method comprises:

(a) under the zinc finger protein KRAZ2-12 condition that expressing human KRAB comprises, cultivate the described through engineering approaches host cell of claim 8;

(b) from culture, isolate and have the active polypeptide of zinc finger protein KRAZ2-12 that people KRAB comprises.

10, a kind of can with polypeptide bonded antibody, it is characterized in that described antibody is the zinc finger protein KRAZ2-12 specificity bonded antibody that can comprise with people KRAB.

11, an analoglike or regulate polypeptide active or the compound of expression is characterized in that they are simulation, promotion, antagonism or the active compound that suppresses the zinc finger protein KRAZ2-12 that people KRAB comprises.

12, compound as claimed in claim 11 is characterized in that it is the polynucleotide sequence shown in the SEQ ID NO:1 or its segmental antisense sequences.

13, the described application of compound of a kind of claim 11, it is characterized in that described compound be used for zinc finger protein KRAZ2-12 that mediator KRAB comprises in vivo, the method for external activity.

14, a kind of disease relevant or method of disease susceptibility of detecting with the described polypeptide of arbitrary claim among the claim 1-3, it is characterized in that it comprises the described polypeptide expression amount that detects, perhaps detect the activity of described polypeptide, perhaps detect and cause described expression of polypeptides amount or active unusual nucleotide diversity in the polynucleotide.

15,, it is characterized in that it is applied to screen stand-in, the agonist of the zinc finger protein KRAZ2-12 that people KRAB comprises, antagonist or inhibitor as the application of polypeptide as described in the arbitrary claim among the claim 1-3; Perhaps be used for the peptide finger print identification.

16, as the application of the described nucleic acid molecule of arbitrary claim among the claim 4-6, it is characterized in that it is used for nucleic acid amplification reaction as primer, perhaps be used for hybridization, perhaps be used to make gene chip or microarray as probe.

17,, it is characterized in that forming with safe and effective dosage and pharmaceutically acceptable carrier the pharmaceutical composition of the relevant unusually disease of the zinc finger protein KRAZ2-12 that comprises as diagnosis or treatment and people KRAB with described polypeptide, polynucleotide or its stand-in, agonist, antagonist or inhibitor as the described polypeptide of arbitrary claim, polynucleotide or application of compound in claim 1-6 and 11.

18, the described polypeptide of arbitrary claim, polynucleotide or the application of compound among the claim 1-6 and 11, it is characterized in that being used for the treatment of as malignant tumour with described polypeptide, polynucleotide or compound, hemopathy, the medicine of HIV infection and immunological disease and all kinds of inflammation.

Images